Pharmaceutical Business review -

Pharmaceutical Business review is using cookies

Continue Learn More

Close

November 15, 2018

Merck’s Keytruda improves overall survival in phase 3 esophageal cancer trial

Merck has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) significantly improved overall survival (OS) rate in the phase 3 Keynote-181 esophageal cancer trial.

Image: Merck’s anti-PD-1 therapy Keytruda. Photo: courtesy of Merck Sharp & Dohme Corp.

November 14, 2018

FDA grants priority review to Tecentriq combo for triple-negative breast cancer

Image: Roche’s Tecentriq gets FDA priority review for triple-negative breast cancer. Photo: courtesy of F. Hoffmann-La Roche Ltd.

November 14, 2018

AbbVie’s Mavyret shows high virologic cure rates in HCV study

Image: AbbVie US headquarters. Photo: courtesy of AbbVie Inc.

Contracts

October 8, 2018

hVIVO signs new contracts with global biopharmaceutical firm

Image: hVIVO has signed new contracts with global biopharmaceutical firm. Photo: courtesy of rawpixel / Unsplash.

Opiant signs contract with BARDA to accelerate OPTN003 product development

BioCryst bags contract to supply RAPIVAB antiviral flu therapy doses to CDC

Drug Manufacturing

Data science company IXICO extends contract with biopharmaceutical firm

Deals

Deals November 14, 2018

AstraZeneca to sell Synagis US rights to Sobi for $1.5bn

Pharmaceutical Business Review

BioTime signs merger deal with Asterias Biotherapeutics

IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics

AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m

Popular

Videos

Suppliers

Spotlight

Pharmaceutical Business Review

BMS, Infinity to assess Opdivo-IPI-549 combo in urothelial cancer

Pharmaceutical Business Review

AstraZeneca to sell asthma and rhinitis drug rights to Covis Pharma for $350m

Pharmaceutical Business Review

Arrowhead, Janssen sign $3.7bn license and collaboration deal